Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : JNT-517
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Otsuka Pharmaceutical
Deal Size : $1,125.0 million
Deal Type : Acquisition
Japan's Otsuka Pharma to pay up to $1.1 bln to acquire Jnana Therapeutics
Details : Through the acquisition, Otsuka will leverage Jana pipelines, which include JNT-517 an allosteric small molecule inhibitor of SLC6A19. It is being evaluated for the treatment of phenylketonuria.
Product Name : JNT-517
Product Type : Small molecule
Upfront Cash : $800.0 million
August 01, 2024
Lead Product(s) : JNT-517
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Otsuka Pharmaceutical
Deal Size : $1,125.0 million
Deal Type : Acquisition
Lead Product(s) : JNT-517
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : JNT-517 is a, oral small-molecule, phenylalanine (Phe) transporter SLC6A19 inhibitor, a potential therapy used to treat PKU, regardless of age or genotype. JNT-517 acts at a novel, cryptic allosteric site...
Product Name : JNT-517
Product Type : Small molecule
Upfront Cash : Not Applicable
January 06, 2023
Lead Product(s) : JNT-517
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : JNT-517
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Bain Capital Life Sciences
Deal Size : $107.0 million
Deal Type : Series C Financing
Details : The proceeds from the funding will be used to progress the company’s lead program JNT-517 in phenylketonuria (PKU), a rare genetic metabolic disease, through a clinical proof-of-concept (POC) study, and...
Product Name : JNT-517
Product Type : Small molecule
Upfront Cash : Undisclosed
November 15, 2022
Lead Product(s) : JNT-517
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Bain Capital Life Sciences
Deal Size : $107.0 million
Deal Type : Series C Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Partner/Sponsor/Collaborator : F. Hoffmann-La Roche
Deal Size : $2,050.0 million
Deal Type : Collaboration
Details : Jnana to leverage its RAPID chemoproteomics platform to discover novel small molecule drugs directed to targets across a diverse range of target classes in cancer, immune-mediated and neurological disease...
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : $50.0 million
November 15, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Partner/Sponsor/Collaborator : F. Hoffmann-La Roche
Deal Size : $2,050.0 million
Deal Type : Collaboration
Lead Product(s) : JNT-517
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : JNT-517, is a small molecule, allosteric inhibitor of SLC6A19, a metabolite transporter responsible for reabsorption of phenylalanine (Phe) in the kidney.
Product Name : JNT-517
Product Type : Small molecule
Upfront Cash : Not Applicable
July 08, 2022
Lead Product(s) : JNT-517
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : JNT-517
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Discovery of JNT-517, which targets SLC6A19, is based on Jnana’s pioneering research and was enabled by RAPID, company’s high-throughput screening-enabled chemoproteomic platform for treatment of PKU ...
Product Name : JNT-517
Product Type : Small molecule
Upfront Cash : Not Applicable
February 23, 2022
Lead Product(s) : JNT-517
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : RA Capital Management
Deal Size : $50.0 million
Deal Type : Series B Financing
Details : Proceeds from this financing will enable Jnana to progress its lead program, SLC6A19 for the treatment of phenylketonuria (PKU) into clinical development, while advancing a pipeline of additional programs...
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
August 18, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : RA Capital Management
Deal Size : $50.0 million
Deal Type : Series B Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery
Partner/Sponsor/Collaborator : F. Hoffmann-La Roche
Deal Size : $1,040.0 million
Deal Type : Collaboration
Details : Under the terms of the agreement, Jnana will partner with Roche on discovery and preclinical development for a broad set of targets across immunology and neuroscience, which Roche will further develop and...
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : $40.0 million
July 21, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery
Partner/Sponsor/Collaborator : F. Hoffmann-La Roche
Deal Size : $1,040.0 million
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?